Tarceva.net

First-line efficacy

Tarceva first-line for EGFR Mut+ NSCLC

Tarceva has been proven to extend progression-free survival (PFS) in both Caucasian and Asian populations.^1,2

EURTAC^1,2

• The first phase III trial in Caucasians with EGFR Mut+ NSCLC
• Tarceva median PFS was nearly double that of first-line chemotherapy

 

 

OPTIMAL^3,4

• Over 1 year PFS in Asian with EGFR Mut+ NSCLC
• Tarceva median PFS was nearly triple that of first-line chemotherapy

 

Post-platinum efficacy

Tarceva post-platinum in advanced NSCLC

Tarceva has demonstrated comparable efficacy to chemotherary (Phase III TITAN study)⁵

   

Tarceva is the only second-line therapy proven to significantly improve Quality of Life (QoL) versus placebo (Phase III BR.21 study)⁶

   

The efficacy of Tarceva is regardless of histology (Phase III TITAN study)⁵

   

or EGFR mutation status:
Tarceva is efficacious in both EGFR Mut+ and wild-type NSCLC (Phase III TITAN study)⁵

 

References

1. Tarceva® (erlotinib) Summary of Product Characteristics, F. Hoffmann-La Roche Ltd., 2011
2. Rosell R, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. The Lancet Oncology - 1 March 2012 ( Vol. 13, Issue 3, Pages 239-246 )
3. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. [published online ahead of print July 22, 2011.] Lancet Oncol. doi:10.1016/S1470-2045(11)70184-X.
4. Zhou C, Wu Y-L, Chen G, et al. Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small-cell lung cancer (NSCLC). J Clin Oncol. 2011;29:Abstract 7520.
5. Ciuleanu T, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. The Lancet Oncology - 1 March 2012 ( Vol. 13, Issue 3, Pages 300-308 )
6. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353(2): 123–32.